Pfizer Continues to use Sofia KnowledgeScan

BioWisdom Limited (BioWisdom), a leader in the provision of healthcare software and healthcare intelligence for the pharmaceutical industry, today announced that Pfizer has signed a further agreement for a BioWisdom KnowledgeScan™ project to assess the market opportunity, potential strategy and clinical trial design for a particular class of compounds. BioWisdom KnowledgeScan™ projects are powered by a suite of state-of-the art technologies to provide unbiased and comprehensive Intelligence to support healthcare-related decision-making for project teams. The service provides a rapid and systematic analysis of large amounts of data and is carried out by an experienced team of healthcare analysts. “We are delighted that Pfizer continue to gain value from our services and we look forward to working closely with them on yet another project.” said Julie Barnes, CSO of BioWisdom.